-
Mashup Score: 0Editorial Board Members needed for Colorectal Cancer - 4 hour(s) ago
Colorectal Cancer provides a concise, readable overview of current and future management options in a fast-moving field, ideal for the busy clinician or healthcare professional. Each issue will provide high-quality Reviews of current and emerging topics, cutting-edge Editorials discussing contentious issues and independent Drug Evaluations assessing individual medicines and their role in current treatment practices. In addition, forward-looking Perspectives and Interviews will give leading experts the
Source: think.taylorandfrancis.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0A plain language summary of the PERSEUS study: daratumumab + VRd treatment options for newly diagnosed multiple myeloma - 25 day(s) ago
Our partner journal Future Oncology has published a Plain language summary of publication describing the first analysis of the PERSEUS study.
Source: www.oncology-central.comCategories: General Medicine News, Oncologists1Tweet-
Read about the PERSEUS trial in a format that can be easily shared with multiple myeloma patients and their caregivers >>> https://t.co/dMwKW8qNwP @phoebejoyho1 @myelomaoslo @AnnaSureda5 @paurotero @IMFmyeloma @HealthTree @LLSusa @SparksCures https://t.co/4XLfaKshGP
-
-
Mashup Score: 1ETOP Slide deck of ESMO Congress 2024 - 2 month(s) ago
Just after the WCLC 2024 Slide deck, we are happy to announce that the ETOP Slide deck of the ESMO Congress 2024 is now available online. The conferences slide decks on the ETOP website (www.etop.ibcsg.org/etop) are designed to highlight and summarize key findings in thoracic oncology from the major congresses. These slide sets are realized with the kind support of Eli Lilly, GSK, Johnson & Johnson and Roche. In addition to the ETOP conferences slide decks, which are designed to highlight and summarize
Source: mailchi.mpCategories: General Medicine News, Oncologists1Tweet-
RT @etop_ibcsg: ETOP Slide deck of ESMO Congress 2024 now online - https://t.co/jZyenPiuG9 https://t.co/KSSJA7enSc
-
-
Mashup Score: 0Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol | Future Oncology - 7 month(s) ago
OPTYX is a multi-center, prospective, observational study designed to further understand the actual experience of patients with advanced prostate cancer treated with relugolix (ORGOVYX®), an oral androgen deprivation therapy (ADT), by collecting clinical and patient-reported outcomes from routine care settings. The study aims to enroll 1000 consented patients with advanced prostate cancer from community, academic and government operated clinical practices across the USA. At planned timepoints, real-world data analysis on treatment patterns, adherence and safety as well as health outcomes and health-related quality-of-life (HRQOL) after treatment discontinuation will be published in scientific peer-reviewed journals and presented at relevant conferences. This study will provide real-world data for practitioners and researchers in their understanding of the safety and effectiveness of relugolix. Clinical Trial Registration: NCT05467176 (ClinicalTrials.gov)
Source: www.futuremedicine.comCategories: General Medicine News, Onc News and JournalsTweet-
OPTYX study aims to generate evidence on ORGOVYX's safety and effectiveness in prostate cancer patients in routine care, including treatment course and post-treatment clinical outcomes. >>> https://t.co/6aQGJkVcb3 https://t.co/7k2bfdHVFh
-
-
Mashup Score: 0Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol | Future Oncology - 7 month(s) ago
OPTYX is a multi-center, prospective, observational study designed to further understand the actual experience of patients with advanced prostate cancer treated with relugolix (ORGOVYX®), an oral androgen deprivation therapy (ADT), by collecting clinical and patient-reported outcomes from routine care settings. The study aims to enroll 1000 consented patients with advanced prostate cancer from community, academic and government operated clinical practices across the USA. At planned timepoints, real-world data analysis on treatment patterns, adherence and safety as well as health outcomes and health-related quality-of-life (HRQOL) after treatment discontinuation will be published in scientific peer-reviewed journals and presented at relevant conferences. This study will provide real-world data for practitioners and researchers in their understanding of the safety and effectiveness of relugolix. Clinical Trial Registration: NCT05467176 (ClinicalTrials.gov)
Source: www.futuremedicine.comCategories: General Medicine News, Onc News and JournalsTweet-
Our partnered journal Future Oncologu recently published a Clinical Trial Protocol of the OPTYX study, which aims to generate evidence on ORGOVYX’s® (relugolix) safety and effectiveness in prostate cancer patients. https://t.co/SRiLZ4tcfy https://t.co/ZJp3IMu6RB
-
-
Mashup Score: 0A journey through value-based oncology care - 7 month(s) ago
What challenges are associated with value-based oncology care and how can these be overcome?
Source: www.oncology-central.comCategories: General Medicine News, Onc News and JournalsTweet-
What challenges are associated with value-based oncology care and how can these be overcome? Read out latest interview feature to find out >>> https://t.co/4FXRho5x9i
-
-
Mashup Score: 0Frontiers in brain tumor research and empowering women in STEM - 8 month(s) ago
Discover the strides being made to unravel the complexities of brain tumors in our latest interview with Karen Noble.
Source: www.oncology-central.comCategories: General Medicine News, Onc News and JournalsTweet-
Discover the strides being made to unravel the complexities of brain tumors in our interview with Karen Noble from @braintumourrsch https://t.co/Pvs9R0pset #IWD24
-
-
Mashup Score: 0A journey through value-based oncology care - 8 month(s) ago
What challenges are associated with value-based oncology care and how can these be overcome?
Source: www.oncology-central.comCategories: General Medicine News, Onc News and JournalsTweet-
How could #AI and value-based care can influence healthcare delivery help create better care journeys? Find out in our latest interview >>> https://t.co/Pw6GjEzfAx
-
-
Mashup Score: 0Championing diversity and inclusion in neuro-oncology - 8 month(s) ago
Explore opportunities for women in neuro-oncology with Dr Macarena Ines De La Fuente who has been the co-chair of the SNO’s Women and Diversity Committee.
Source: www.oncology-central.comCategories: General Medicine News, Onc News and JournalsTweet-
Explore opportunities for women in neuro-oncology, with insights from @SylvesterCancer's Macarena de la Fuente, who has been the co-chair of the Society for Neuro-Oncology’s Women and Diversity Committee: https://t.co/MUTIroqEpz @NeuroOnc
-
-
Mashup Score: 0
How can MRI-guided radiation therapy offer in terms of real-time insights into glioblastoma disease progression?
Source: www.oncology-central.comCategories: General Medicine News, Onc News and JournalsTweet-
Radka Stoyanova @SylvesterCancer is using AI to both detect glioblastoma tumor volume changes and build models to predict the response of a patient to a particular treatment. https://t.co/dQdRQ5kARo
-
📢 Colorectal Cancer is recruiting! The journal is looking for new Editorial Board Members to help shape the future of the journal. Learn more and apply today! https://t.co/e8qrCQa7it #ColorectalCancer #AcademicPublishing